Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386815 | 1.00 | GPR119 (0.40) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL8064199 | 1.00 | GPR119 (0.40) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL376575 | 1.00 | GPR119 (0.40) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL3243612 | 1.00 | GPR119 (0.40) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL15836693 | 0.87 | GPR119 (0.40) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL2536245 | 0.86 | CHRM2 (0.40) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL2544292 | 0.86 | CHRM2 (0.40) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL16059514 | 0.86 | CHRM2 (0.40) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL1549880 | 0.86 | CHRM2 (0.40) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL16729598 | 0.86 | CHRM2 (0.40) | GPR119CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4565579-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | Theras, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-0557122-B1 | A production method for sulfamide | SHIONOGI & CO (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5539102-A | ANTIBIOTIC SYNTHESIS BY DEHYDRATION REACTION OF ALCOHOL WITH OXYCARBONYLSULFAMIDE IN THE PRESENCE OF TRIVALENT PHOSPHOROUS | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0659178-A4 | CHIRAL QUINOLONE INTERMEDIATES. | ABBOTT LAB (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0659178-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994006766-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5252747-A | Chiral quinolone intermediates | ABBOTT LABORATORIES (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0557122-A1 | A production method for sulfamide | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | GPR119 1117/4885CHRM2 4224/4885CHRM1 4229/4885 |
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885CHRM2 4498/4885CHRM1 4157/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885CHRM2 4498/4885CHRM1 4157/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885CHRM2 4498/4885CHRM1 4157/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885CHRM2 4498/4885CHRM1 4157/4885 |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885CHRM2 4498/4885CHRM1 4157/4885 |
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | GPR119 1374/4885CHRM2 3607/4885CHRM1 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.